Item 2.02. Results of Operations and Financial Condition.
On January 5, 2023, Arbutus Biopharma Corporation (the "Company") issued a press
release (the "Press Release") announcing its 2023 corporate objectives and
provided certain estimated and projected financial information, including its
estimated cash, cash equivalents and investments as of December 31, 2022. The
amounts included in the Press Release are preliminary, have not been audited and
are subject to change upon completion of the Company's audited financial
statements for the year ended December 31, 2022. Additional information and
disclosures would be required for a more complete understanding of the Company's
financial position and results of operations as of December 31, 2022. A copy of
the press release is filed herewith as Exhibit 99.1 and is incorporated by
reference herein.
On January 5, 2023, the Company posted an updated corporate presentation on its
website at www.arbutusbio.com (the "Corporate Presentation"), which included the
Company's estimated cash, cash equivalents and investments as of December 31,
2022. A copy of the Corporate Presentation is filed herewith as Exhibit 99.2 and
is incorporated by reference herein.
Item 8.01. Other Events.
On January 5, 2023, the Company issued the Press Release, a copy of which is
filed herewith as Exhibit 99.1 hereto and is incorporated by reference herein.
A copy of the Corporate Presentation is filed herewith as Exhibit 99.2 hereto
and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number Description
99.1 Press release dated January 5, 2023
99.2 Corporate Presentation January 5, 2023
104 Cover Page Interactive Data File (embedded within the
Inline XBRL document)
© Edgar Online, source Glimpses